Biohaven Ltd

NYSE:BHVNUnited States

Today

Show headlines and story abstract

• Sector Update: Health Care Stocks Mixed Pre-Bell Thursday, from 13 hours ago by MT Newswires

  13 hours ago by MT Newswires
  Companies Mentioned: IBB, ELV, XLV, CERE, BHVN
  09:12 AM EDT, 04/18/2024 (MT Newswires) -- Health care stocks were mixed pre-bell Thursday, with the iShares Biotechnology ETF (IBB) down 0.1% and the Health Care Select Sector SPDR Fund (XLV) 0.4% higher. Elevance Health (ELV) stock was up more tha...

• Biohaven Prices $230 Million Public Share Offering, from 14 hours ago by MT Newswires

  14 hours ago by MT Newswires
  Companies Mentioned: BHVN
  08:27 AM EDT, 04/18/2024 (MT Newswires) -- Biohaven (BHVN) said Thursday it has priced an underwritten public offering of about 5.6 million shares at $41 each for gross proceeds of about $230 million. The biopharmaceutical company granted underwrit...

• Biohaven Announces Pricing of $230 Million Public Offering of Common Shares, from 16 hours ago by PR Newswire

  16 hours ago by PR Newswire
  Companies Mentioned: BHVN

  Biohaven Ltd.(NYSE: BHVN), a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology, today announced the pricing of its underwritten public offering of 5,609,757 of its common shares at a price to the public of $41.00 per share. In addition, Biohaven has granted the underwriters a 30-day option to purchase up to an additional 841,463 common shares at the public offering price, less underwriting discounts, and commissions. The gross proceeds from the offering are expected to be approximately $230 million before deducting underwriting discounts and commissions and offering expenses payable by Biohaven. The offering is expected to close on April 22, 2024, subject to satisfaction of customary closing conditions. Biohaven intends to use the net proceeds received from the offering for general corporate purposes.

• Biohaven Announces Pricing of $230 Million Public Offering of Common Shares, from 16 hours ago by Dow Jones

  16 hours ago by Dow Jones
  Companies Mentioned: BHVN
  
  Biohaven Announces Pricing of $230 Million Public Offering of Common Shares
  
  PR Newswire
  
  NEW HAVEN, Conn., April 18, 2024
  
  NEW HAVEN, Conn., April 18, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology, today announced the pricing of its underwritten public offering of 5,609,757 of its common shares at a price to the public of $41.00 per share. In addition, Biohaven has granted the underwriters a 30-day option to purchase up to an additional 841,463 common shares at the public offering price, less underwriting discounts, and commissions. The gross proceeds from the offering are expected to be approximately $230 million before deducting underwriting discounts and commissions and offering expenses payable by Biohaven. The offering is expected to close on April 22, 2024, subject to satisfaction of customary closing conditions. Biohaven intends to use the net proceeds received from the offering for general corporate purposes.